GENETIC TECHNOLOGIES LIMITED — Investor Presentation 2013

Jan 6, 2013

==> picture [595 x 69] intentionally omitted <==

==> picture [595 x 69] intentionally omitted <==

ASX ANNOUNCEMENT January 7[th] , 2013

---

Presentation at Cowen’s 2013 Asia Pacific Life Science Showcase

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) advises that its Chief Executive Officer, Ms. Alison Mew, will present the attached presentation at the above conference being held in San Francisco, California on Monday, January 7[th] , 2013 (US time).

---

FOR FURTHER INFORMATION PLEASE CONTACT

Mr. Thomas G. Howitt Company Secretary

Genetic Technologies Limited Phone: +61 3 8412 7000

Genetic Technologies Limited ABN 17 009 212 328 • Website : www.gtglabs.com • Email : info@gtglabs.com Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040

Genetic Technologies presents: Breast Cancer Risk. Corporate Overview An Emerging Market Segment.

This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance of Genetic Technologies Limited and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Genetic Technologies Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Genetic Technologies’ current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ

• Global diagnostics testing business focused on women’s health

• NASDAQ: GENE ; ASX: GTG

• Headquartered in Melbourne, Australia

• Sales operations in U.S. (via subsidiary, Phenogen Sciences) & Australia

• TM

• � Lead product, BREVAGen , a non-familial breast cancer risk test first launched July, 2011 in U.S. and now available across 49 states

• Leveraging more than 20 years of experience as a genetic testing business

• Sustainable cash flow provides operational base for expansion

• Globally certified laboratory in Melbourne (CLIA, ISO, RCPA, NATA)

• IP out-licensing program generates recurring revenue stream

� Over 70 licenses to date ($70M+ in revenue) - record nine licenses granted

• Produces both a 5 year and lifetime percentage risk of developing breast cancer

• Allows physicians to recommend a personalized ‘Breast Health Plan’ outlining better surveillance strategies and proactive changes, tailored to each patient’s lifestyle

• Uses independent guidelines from

• First fully prospectively-validated SNP panel to be published in a major journal

• Conducted a 3,300 patient clinical validation trial in U.S., including 1,664 postmenopausal women, as well as a control group of 1,636 cancer-free women

• Reclassified approximately 64% of women who had been categorized as “intermediate risk” (1.5% to 2.0% five year risk) based on GAIL score alone

• Reclassified 33% of women compared to the GAIL score – reducing the

• A Breast Health Pl ~~an~~ motivates women to adopt physician

recommendations

• Detecting breast cancer early is the key to fighting it

• Only 59% of women have had a mammogram

• BREVAGen helps solve the over/under use of the mammography debate by

• Dominant market positions established across PacRim region

• Globally accredited laboratory

• Decades of experience producing & selling genetic tests

• Oncology testing Australia, Asia & EU

• Contracted provider to NSW Police Force for volume crime forensic testing

• � 70+% market share for Australia/New Zealand paternity testing

• Exclusive provider of genetic testing for most PacRim canine breed clubs

• Leading contracted provider of paternity

• Non-coding DNA patent estate provides substantial non-dilutive funding

• Over 70 licenses, $70M+ revenue received to date

• Contracted annuity stream of $5.0M through 2015

• Further U.S. and EU activities ramping up in 2013

Number	Title	Expiration date
‘762	Genetic Mapping	2015
‘033	Methods for Identifying Matching Groups	2022
‘589	Methods for Genomic Analysis	2022
‘025	Genetic Analysis Systems and Methods	2022

� RareCellect™: Next-gen prenatal testing

• Current market offers testing at 11-13 weeks into pregnancy with a 20% missed abnormality rate. Invasive tests cause up to 8% miscarriage rate (average 1.5%)

• RareCellect offers an earlier risk free method via cervical fetal DNA sampling of chromosomal genetic prenatal testing

• Prenatal testing market $2B in U.S. alone

• Looking to divest/partner asset – in talks with various potential partners

� ImmunAid™: Immune system research

• Based on “on/off” cycle of immune system in patients with chronic/infectious disease

• Examining novel approach to cancer therapy through timely reversal of immune system suppression

• Key patents granted in EU, with further patents expected in U.S.

(AUD millions) Revenue / gains Operations Licensing Net profit / (loss) Cash	2012 5.1 1.6 3.5 (2.6) 8.1	2011 3.3 1.6 1.7 (2.5) 13.3

Shares outstanding 475.0 million ADRs (@30:1 ratio) 15.8 million Top 20 shareholders 69.7% Total shareholders 3,020 Options outstanding 9.9 million

(employees only)

Market cap (@ $0.08) AUD 38.8 million

• BREVAGen™ market development

• Build on successful launch

• Expand territories and specific women’s health channels

• Expand and develop BREVAGen #2 – increased SNPs; additional ethnicities

• Assessing new product acquisitions

• On or close to market assets

• Similar sales channels and marketing synergies to existing franchise: women’s health, oncology

• Current commercial business and IP strategy continues to support growth

• Seeking to monetize non-core programs

Contact Information

Alison Mew Chief Executive Officer